Skip to main content
. 2021 Jun 20;13(12):3074. doi: 10.3390/cancers13123074

Figure 7.

Figure 7

Individual clinical courses of all patients treated with immunotherapy who discontinued treatment in the absence of disease progression. Data is presented from treatment initiation to the last follow-up or death. Patients were sorted according to disease progression and steroid exposure. Patients achieving CR were less likely to have disease progression at treatment discontinuation (24%), compared to patients achieving PR or SD as best response (50% and 100%, respectively; odds ratio (OR), 0.31; p = 0.02 for CR versus PR). Median time from treatment discontinuation to progression was 12 m for patients with CR, and 5.9 m and 6 m for patients with PR and SD, respectively. Steroid therapy (prednisolone equivalent dose >10 mg) during treatment was associated with a higher likelihood of disease progression after treatment discontinuation (OR 2.93, 95% CI 1.20–7.15, p = 0.018). Abbreviations: CR—complete response; PR—partial response; SD—stable disease; PD—progressive disease; OR—odds ratio.